Society of Surgical Oncology Podcast

Cryoablation is emerging as a minimally invasive alternative to lumpectomy for select women with early-stage breast cancer. The FROST trial (NCT01992250) was a prospective, phase 2 multicenter study evaluating the outcome of cryoablation in the management of stage I, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative invasive ductal carcinoma.

Cryoablation is emerging as a minimally invasive alternative to lumpectomy for select women with early-stage breast cancer. The FROST trial (NCT01992250) was a prospective, phase 2 multicenter study evaluating the outcome of cryoablation in the management of stage I, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative invasive ductal carcinoma.

Dr. Holmes explains how cryoablation—a targeted, minimally invasive technique that freezes tumors—can serve as an effective and less toxic alternative to traditional surgery and radiation.

Dr. Holmes explains how cryoablation—a targeted, minimally invasive technique that freezes tumors—can serve as an effective and less toxic alternative to traditional surgery and radiation.

By now, many of you have heard that the FDA has approved the use of the ProSense (IceCure) cryoprobe for the treatment of breast cancer with cryoablation. While this represents a major milestone, it is only the beginning of the process of achieving full Medicare and commercial insurance coverage for breast cancer cryoablation.

By now, many of you have heard that the FDA has approved the use of the ProSense (IceCure) cryoprobe for the treatment of breast cancer with cryoablation. While this represents a major milestone, it is only the beginning of the process of achieving full Medicare and commercial insurance coverage for breast cancer cryoablation.

Featuring Dr. Dennis Holmes

Featuring Dr. Dennis Holmes

Dr. Dennis R. Holmes unveils the FROST trial’s 5‑year results showing that tumor‑freezing (cryoablation) is as effective and safer than lumpectomy for Stage I breast cancer, with most patients avoiding lymph‑node surgery. The newsletter includes his ASBrS conference talk, a procedure video, and a thank‑you to the women who made these advances possible.

Dr. Dennis R. Holmes unveils the FROST trial’s 5‑year results showing that tumor‑freezing (cryoablation) is as effective and safer than lumpectomy for Stage I breast cancer, with most patients avoiding lymph‑node surgery. The newsletter includes his ASBrS conference talk, a procedure video, and a thank‑you to the women who made these advances possible.

Featuring Dr. Dennis Holmes and Dr. Suzanne Klimberg, Speaking on Breast Cancer Ablation

Many women fear that breast needle biopsies increase the risk of cancer spread due to tumor cell displacement. Although evidence suggests minimal impact on breast cancer loco-regional recurrence or distant metastasis, technical modifications of needle biopsy procedures, including the use of cryoablation, can reduce the potential risks of breast needle-biopsy-induced cancer cell displacement to reduce patient fears of breast needle biopsy procedures.

Many women fear that breast needle biopsies increase the risk of cancer spread due to tumor cell displacement. Although evidence suggests minimal impact on breast cancer loco-regional recurrence or distant metastasis, technical modifications of needle biopsy procedures, including the use of cryoablation, can reduce the potential risks of breast needle-biopsy-induced cancer cell displacement to reduce patient fears of breast needle biopsy procedures.

The following is a 74 year old who underwent cryoablation of a 19 mm invasive ductal carcinoma. She remains cancer free 8 years after cryoablation.

The following is a 74 year old who underwent cryoablation of a 19 mm invasive ductal carcinoma. She remains cancer free 8 years after cryoablation.

Breast cryoablation presents a promising alternative to surgery while offering the benefits of a minimally invasive procedure with minimal risks.

Breast cryoablation presents a promising alternative to surgery while offering the benefits of a minimally invasive procedure with minimal risks.

Dr. Holmes is author of the newly published article, "Breast cancer care during a pandemic: an opportune time for cryoablation?" in Breast Cance...

Dr. Holmes is author of the newly published article, "Breast cancer care during a pandemic: an opportune time for cryoablation?" in Breast Cance...

The world is now abuzz with news about Coronavirus (COVID-19), the viral disease that has recently taken the world by storm.

The world is now abuzz with news about Coronavirus (COVID-19), the viral disease that has recently taken the world by storm.

This month’s newsletter draws attention to a recent JAMA Oncology editorial, De-escalating Breast Cancer Surgery—Where is the Tipping Point (Dec...

This month’s newsletter draws attention to a recent JAMA Oncology editorial, De-escalating Breast Cancer Surgery—Where is the Tipping Point (Dec...

Apart from the appeal of cryoablation as a minimally invasive alternative to surgery, many women are drawn to cryoablation because of its...

Apart from the appeal of cryoablation as a minimally invasive alternative to surgery, many women are drawn to cryoablation because of its...

This letter to the editor was offered in response to a November 2019, Desert Sun article regarding a surgeon who was placed on probation by the...

This letter to the editor was offered in response to a November 2019, Desert Sun article regarding a surgeon who was placed on probation by the...

Cryoablation is a well-established technique to treat fibroadenomas. Pilot studies suggest this could be an effective non-surgical treatment for breast cancer. American College of Surgeons Oncology Group Z1072 is a phase II trial exploring the effectiveness of cryoablation in the treatment of breast cancers.

Cryoablation is a well-established technique to treat fibroadenomas. Pilot studies suggest this could be an effective non-surgical treatment for breast cancer. American College of Surgeons Oncology Group Z1072 is a phase II trial exploring the effectiveness of cryoablation in the treatment of breast cancers.